The hearing concerned three separate charges against Mr Mallon. The first charge related to his treatment of a Labrador named Bailey on 15 September 2016 in which he was alleged to have euthanased the animal without the owner’s consent, after having been called out to her home following concerns about Bailey’s arthritis.
The second charge related to failure to keep adequate clinical records for Bailey between 14 March 2015 and 30 September 2016.
The third charge related to failing to respond adequately to communications regarding Bailey’s treatment from his owner between 15 September 2016 and 6 January 2017.
At the outset of the hearing, Mr Mallon admitted the charge relating to keeping inadequate clinical records. However, he disputed the College’s evidence regarding euthanasing Bailey without his owner’s consent. He claimed to have had previous discussions with the owner’s husband about euthanasia six months prior to the event, that he had been informed that the owner had mentioned a possible need for euthanasia in a phone call earlier that day and that, on attending the premises, the owner’s mother had mentioned a need to put Bailey down. During the course of the hearing, Mr Mallon accepted that these incidents could not have reasonably amounted to consent.
The Committee also heard and accepted evidence that the owner’s mother, who was present when Mr Mallon visited, had wished to contact her daughter to inform her about the planned euthanasia but that Mr Mallon proceeded to euthanase the animal regardless. The Committee also noted there was no contemporaneous clinical records nor any signed consent form for the procedure. Furthermore, the Committee found no evidence that there was a need to put Bailey down immediately and no reason why Mr Mallon could not have waited until the owner was present and had given consent.
Regarding the third charge, the Committee heard that the communications between Mr Mallon and the owner amounted to a telephone call on 15 September and a letter from the owner dated 16 September in which she asked a number of questions about Bailey’s treatment. The Committee accepted that, during the phone call, the owner had made a number of threats to Mr Mallon that had caused him to be fearful for himself and his property. Furthermore, the Committee found that there were a number of points in the subsequent letter to which he could have responded and the Committee noted that, when he was giving evidence, Mr Mallon expected the owner to apologise to him and withdraw the threats before he would engage with her complaint. The Committee therefore found the charge proved.
After finding the charges proved the Committee then went on to consider whether, individually and cumulatively, they constituted serious professional misconduct. It found this to be the case in respect of all three charges. Commenting on the first charge Jane Downes, chairing the Committee and speaking on its behalf, said: "He should have allowed the owner to come to an informed decision. He had an opportunity to obtain informed consent and he failed in this regard. By failing to take this opportunity he overrode the possibility of allowing [the owner] the right to choose whether to be present or to discuss Bailey’s prognosis."
The Committee then went on to consider the sanction for Mr Mallon and heard from a number of clients and professional colleagues who spoke to his skill, care, passion for animal welfare and high standing in his community. The Committee also considered 30 written testimonials from clients. In mitigation, the Committee also considered Mr Mallon’s otherwise unblemished 30-year career, the fact it was a single isolated event related to one animal and the fact that there was no evidence of systemic or repeated behaviour.
Jane Downes added: "The Committee concluded that the appropriate and proportionate sanction is a reprimand in this case. The Committee is confident that Mr Mallon will not repeat the conduct identified in this case again. The Committee wishes to advise Mr Mallon of the need to reflect on the outcome of this case, the need to have clear communication systems in place at this practice that are effective so as to avoid any possibility of miscommunication. The Committee further advises Mr Mallon of the need to be familiar and comply with all aspects of the Code [of Professional Conduct for Veterinary Surgeons] and its associated guidance, particularly in respect of keeping clinical records, informed consent and effective complaint management."
The UK has now seen a total of 169 confirmed cases of Alabama Rot across 38 counties, since 2012. Six cases were confirmed in 2012, climbing to 40 in 2017 and 46 so far in 2018.
The new research, which was carried out in conjunction with the Royal Veterinary College, found that almost 95% of confirmed cases of Alabama Rot have occurred between November and May, with the highest number of cases being reported in February.
It also found most of the cases have been confirmed in western and southern parts of England, with the highest number found in West Sussex, Dorset, southern Hampshire, Greater Manchester and Monmouthshire. Far fewer cases have been reported from the eastern half of the country and East Anglia in particular.
David Walker, Head of medicine at Anderson Moores and co-author of the research, said: "This research, which was funded by the New Forest Dog Owners Group and the charity Alabama Rot Research Fund, was designed to look for geographical patterns, as well as environmental and climatic risk factors.
"A distinct seasonal pattern is suggested, with the vast majority of cases occurring between November and March, and limited cases over the summer months – just 6.5% of cases have been confirmed from June to October.
"In the scientific world a lot of research is not earth-shattering, but it all builds together and little by little we make progress.
"This information is good in terms of how we manage the next stage of research, however we need to be careful and not jump to any conclusions at this point".
Researchers say the disease has been reported in a wide range of breeds (35 in total) but, due to the small number of cases, it is not yet possible to say with any certainty whether a specific breed has an inherently increased or decreased risk of the disease. Any patterns may simply be the result of varying breed populations in different parts of the country.
Dr Huw Stacey, vet and director of clinical services at Vets4Pets, has been supporting research on the condition for a number of years. He said: "Since we held the first Alabama Rot conference in May 2017, vets and relevant professionals have been working hard to understand more about the condition.
"We know how the disease presents and how it affects dogs internally, and this research adds some interesting information that may help to increase vets’ index of the suspicion for the disease.
"The information on climate and ground type will help us further explore possible triggers for the disease, but at the moment we can’t say if any breeds are more likely to develop the disease.
"The first sign of the disease that is normally seen is a skin sore or lesion that isn’t caused by a known injury. Most commonly these sores are found on the lower half of the leg and appear as a distinct swelling, a patch of red skin or are open and ulcer-like.
"With 46 cases in 2018 already, it is understandably very worrying for dog owners, but we think the increase in cases is partially due to an increased awareness of the disease.
"However, this disease is still very rare, so we’re advising dog owners to remain calm but vigilant, and seek advice from their local vet if their dog develops unexplained skin lesions.
"While this research may be a stepping stone to finding the cause of Alabama Rot, there is currently no known way to prevent a dog from contracting the disease."
*also clinically known as
Animalcare has announced the launch of Fungiconazol (ketoconazole), the UK's only veterinary licenced antifungal tablet for dogs, indicated for the treatment of ringworm.
Each Fungiconazol tablet contains 200 or 400mg of ketoconazole, to be administered at a dosage of 10mg per kg bodyweight once daily. Each tablet can be split into quarters or halves, allowing accurate treatment for dogs from 5kg (¼ x 200mg tablet daily) to 60kg (1½ x 400mg tablet daily) and beyond. The hypoallergenic chicken flavoured tablets mean that Fungiconazol is also suitable for dogs with food allergies or atopic dermatitis.
Animalcare Product Manager Tony Liepman said "This is a great addition to our antimicrobial range, and shows once again that it’s possible for us to be innovative without breaking anyone's budget. With the supply of the first and only licensed canine antifungal tablet on the market, we have ensured that all veterinary practices have access to Animalcare’s Technical Support department for further advice on treatment or its use in their patients."
Both 200mg and 400mg presentations of Fungiconazol, in 100 tablet blister packs, are now available from wholesalers.
For further information contact Animalcare on 01904 487687, or speak to your regional Animalcare representative (found at www.animalcare.co.uk/contact-us).
The one hour meeting will take place at 8:00pm on Wednesday 5th May. It will be recorded and available after the event. Simon will begin with a brief background to IR35 and how the system has worked historically. He will then explain what has changed and what the options are for locums (and the impact on their income). The meeting will consider things like the criteria that locums need to fulfill to qualify as sole traders, how to use CEST and alternatives to IR35. There will then be an opportunity to ask questions. All registrants are being invited to submit questions in advance, and the plan is that on the night, groups of four participants will be invited to put their questions to Simon together, in a sort of mini discussion. This'll be repeated as many times as possible within the hour. The meeting is the first in a series planned for VetSurgeon and VetNurse members to meet up, share ideas and make better connections with each other. To register, visit: https://us02web.zoom.us/meeting/register/tZ0rf-GurDIsGdP7UXuJn8TJChZiyXMbdKP_
For more information about Moore Scarrott, see: https://www.moore-scarrott.co.uk
Virbac Animal Health has announced that its medical castration implant Suprelorin 9.4mg has received a marketing authorisation for use in ferrets.
The neutering of male ferrets (hobs) is recommended to suppress fertility, decrease odour and reduce territorial aggressive behaviour and urinary marking¹. According to Virbac, Suprelorin offers temporary sterilisation but without the need for surgery, and its use prevents the high Luteinizing hormone (LH)/Follicle-stimulating hormone (FSH) levels which occur following surgery and which can play a role in the development of hyperadrenocorticism².
Suprelorin is a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin. Once injected under the skin of healthy, sexually mature and entire ferrets, the continuous low release of deslorelin from the implant causes an interruption of the HPA circuit, leading to a reduction in LH/ FSH levels and therefore testosterone production. This results in a reduction of libido, spermatogenesis and testicle size.
The implant lasts for up to four years, at which stage the ferret can be re-implanted to maintain the effect.
Chris Geddes MRCVS, Virbac Product Manager, said: "For owners looking for a surgery-free route to the castration of male ferrets and the problems it can cause, Suprelorin provides a simple and effective alternative."
Suprelorin 4.7mg has been available for use in dogs since 2008. Suprelorin 9.4mg was launched in 2011.
For further information, please contact your Territory Manager or call Head Office on 01359 243243.
References:
CEVA Animal Health is giving away a key ring torch with every three bottles of Rehydion gel®, its product for scouring calves.CEVA says the deal is to highlight the fact that Rehydion gel® is currently the only oral rehydration treatment that can be added to milk, with guaranteed milk clotting. According to the company, Rehydion gel® has faster, guaranteed milk clotting and helps to maintain a low abomasal pH. Its high palatability and efficient dilution in milk allows weight gain to continue, even in cases of severe scour. It also has a high Strong Ion Difference (SID) which effectively suppresses acidosis. Rehydion gel® is fast to mix by simply shaking the hand-held bottle. Rehydion gel's® consistency means that precise doses of alkalinising agents and electrolytes can be squeeze-delivered with ease. In beef systems the product is time-saving, convenient and minimises stress as it can be given neat, meaning there is need for the calf to be separated from its dam. One bottle provides enough for eight, two-litre calf feeds or 160 feeds for lambs. The distinctive yellow top also acts as a handy measuring cap.
Further information and product literature is available from Martin Gough on 01494 781510.
Researchers from Nottingham Trent University and the Royal Veterinary College found that exertion or exercise – which could include dogs walking, playing or running with their owners – was responsible for three quarters (74%) of heat stroke cases. Many of these cases were in the summer months.
For the study, the researchers analysed the clinical records of more than 900,000 UK dogs. They found that 1,222 had received veterinary care for heatstroke at some point during their lives, almost 400 affected in a single year. 14.2% of them died as a result of their heatstroke.
Hot weather alone was responsible for 13% of cases, while travelling or being left in hot vehicles accounted for 5% of cases. Other triggers for heat stroke included undergoing treatment at a veterinary surgery or a dog grooming parlour, being restricted to hot buildings or trapped under blankets.
Male dogs and younger dogs were more likely to develop heatstroke triggered by exercise, with breeds including the Chow Chow, Bulldog, French Bulldog, Greyhound, English Springer Spaniel, Cavalier King Charles Spaniel and Staffordshire Bull Terrier at increased risk.
Older dogs and brachycephalic breeds, such as bulldogs and pugs, were at increased risk of getting heatstroke just by sitting outside in hot weather. Brachycephalics were particularly at risk of developing heat stroke if left in hot cars.
Emily Hall, a researcher and veterinary surgeon in Nottingham Trent University’s School of Animal, Rural and Environmental Sciences said: "It appears that people are hearing the message about the dangers of hot vehicles, but campaigns to raise public awareness about heat-related illness in dogs need to highlight that dogs don’t just die in hot cars. Taking a dog for a walk or a run in hot weather can be just as deadly so consider skipping walks altogether during heatwaves, or be sure to take dogs out early in the morning whilst it’s still cool.
Dr Dan O’Neill, co-author and senior lecturer in companion animal epidemiology at The Royal Veterinary College, said: “The UK is currently in the midst of an ill-fated love affair with flat-faced dogs. Demand for breeds such as the French Bulldog, Pug and British Bulldog has soared during the Covid19 lockdown. I appeal to owners to put the needs of the dog ahead of their own desire to possess something that looks cute."
Reference
French veterinary surgeons went on strike yesterday, and 10,000 marched on the streets of Paris in protest at Government plans to restrict their ability to supply certain farm animal antibiotics.
According to the National Union of Practicing Veterinarians (SNVEL), French veterinary surgeons saw the Government plans as an attack on their integrity and competence, and called for the strike, the first of its kind in history.
As a result of the strike, French Ministers have apparently pledged to retract their plans, something which was welcomed by veterinary representatives at the end of the march to the Ministry of Health (see right; click to enlarge).
At the same time, the SNVEL organised a 'Day Without Veterinarians' in all the French Departments. Given that there are only 11,000 practicing vets in France, 10,000 of whom were in Paris, that bit can't have been a particularly difficult logistical challenge.
Purina carried out a survey earlier this year which revealed the different ways British cat owners manage sensitivity to cat allergens2. They included removing the cat when sensitivities to allergens act up (76%), restricting the cat to specific places in the home (75%), using special cat products on the cat such as dander removers or allergen sprays (64%), bathing the cat (56%) and taking the cat to a groomer (52%).
92% also use a high-quality vacuum cleaner, 66% put covers on their furniture and 26% clean their home and furniture daily to remove traces of cat hair.
Dr Ebenezer Satyaraj, PhD, immunologist for Nestlé Purina Research and lead investigator on the research that led to the development of Pro Plan LiveClear, said: “Many people think that cat hair or dander is the allergen, but it’s actually what’s on it – the major cat allergen called Fel d 1, a protein that cats produce naturally in their saliva.” 3,4
All cats produce Fel d 1, regardless of breed, age, hair length, sex or body weight, but at differing levels.4-6 When cats groom themselves, Fel d 1 gets on the hair and skin through the saliva and with shedding, it eventually gets into the home environment. Feld d 1 attaches itself to any surface it comes into contact with and remains in houses for over a year or more.
Purina says Pro Plan LiveClear contains a specific protein, sourced from eggs, which binds itself to the Fel d 1 and safely neutralises it in the cat’s mouth, thereby reducing the amount of active allergen shed in the environment 7,8.
In a study, feeding Pro Plan LiveClear was shown to reduce the allergens on cat hair and dander by an average of 47%, starting in the third week of daily feeding7.
There have been no studies as yet which have tested the effect of this allergen reduction on human symptoms, but Purina says anecdotal evidence from consumers who have tried the product has been positive thus far.
Amena Warner, Head of Clinical Services at Allergy UK said: "Amena Warner, Head of Clinical Services at Allergy UK said: "There are a number of ways in which cat owners try to manage their exposure to cat allergens and keep their symptoms at bay, including taking antihistamines, using inhalers for quick symptoms relief as sensitivity to cat allergens is often linked to allergy-related asthmas, regularly cleaning and hoovering, bathing and grooming the cat by non-allergic family members. And if these measures do not work, current medical advice is often to relinquish the pet to limit exposure to the allergens.
"Every cat is unique though, and so the level of Fel d 1 they produce varies, just as every person's sensitivity level to these allergens is different. That is why there is no ‘one size fits all’ way to manage exposure to cat allergens. Every little bit helps so a combination of management tools often works best to help reduce cat allergens in your home - the combination is unique to your lifestyle. We welcome the development of Pro Plan LiveClear, which when used as part of a cat allergen management regime, could be a meaningful extra tool for affected households.”
Purina says Pro Plan LiveClear is not intended to replace other cat allergen-reduction strategies but to add another measure that can help reduce the cat allergen burden in cat households.
Pro Plan LiveClear is available at Pets at Home retail stores and from the Purina online shop as a complete life-stage range with six products tailored for Kitten, Adult and Adult 7+.
References
The company behind the research shall remain nameless because whilst it has a great PR agency which produces some interesting press releases, the tight so-and-sos have never spent so much as a single bean supporting the VetSurgeon.org community with any advertising. And whilst we always publish stories that are of genuine importance and even the odd piece of PR propaganda-puff, we have to draw the line somewhere.
Where was I? Oh yes. 57 of the 100 veterinary surgeons (64 practice owners, 7 senior partners and 29 employed vets) surveyed by the unnamed company said they think their practice could do more to prevent the spread of infection.
79 said they are concerned that they are not consistently following correct hygiene protocols.
54 said they need more staff training and 53 said they want to be able to give staff more time between appointments to allow longer for more thorough disinfection of equipment and surfaces.
The company says its research suggests vets may need to do more to educate pet owners on the threats of poor hygiene and the spread of infection. Only 14 of the 100 veterinary surgeons surveyed believe that pet owners know enough about this, and pets not being vaccinated against disease was the second most common frustration vets felt about owners’ standards of pet care.
An unnamed spokesperson from the unnamed company said: "A busy vets practice is naturally focused on the care and health of its animal patients, however, hygiene standards are a vital aspect of this. With a full schedule of appointments, it can be difficult to effectively ensure all infection control procedures are covered. As a result, it’s easy for vets to overlook the important role laundry has to play as part of this process."
Incidentally, if you'd like to buy laundry equipment from a company that does support VetSurgeon.org, we recommend Eickemeyer.
The RCVS statement, which can be read in full here, highlighted the fact that there is no body of evidence that homeopathy is effective and nor is it based on sound scientific principles. It should therefore be considered as complementary rather than alternative to treatments which are based on sound scientific principles, or for which there is a recognised evidence base.
In fact, the RCVS statement said nothing new. The principle that veterinary surgeons must first prescribe licensed medicines tested for safety and efficacy is enshrined in the Veterinary Medicines Regulations 2013, which say that if there is no veterinary medicine authorised in the United Kingdom for a condition in a particular species the veterinary surgeon responsible for the animal may treat with a veterinary medicine authorised for use in another animal species or for another condition in the same species, or, failing that, either a medicine authorised in the UK for human use, or a veterinary medicine authorised in another member state for use with any animal species in accordance with the Special Import Scheme, or a specially prepared (extemporaneous preparation or special) medicine, or exceptionally a medicine imported from outside the EU.
There are no homeopathic treatments listed by the VMD as 'authorised', just a handful of homeopathic preparations listed as 'registered', something which, as the BAHVS itself points out, means they have not been subjected to the same evaluation as authorised medicines or tested for efficacy.
The BAHVS is fond of using anecdote as evidence of efficacy (see the endorsements at the foot of this page: http://www.bahvs.com/), so one veterinary surgeon has been inviting colleagues to share their experiences of homeopathy causing harm on social media, in order to produce an infographic (pictured above right, click to enlarge) highlighting the very real harm caused when, for example, owners 'vaccinate' against parvo with homeopathic nosodes, only to have a dead litter on their hands.
The draft infographic can be found here.
Do you have a story to add to it? Share it here.
Elanco says OA is a condition which is estimated to affect one in four dogs, but it is often labelled by owners as "just old age". This, says the company, may lead to missed diagnosis and dogs not receiving the care they need.
To try and help address the issue, Elanco has partnered with the founder of Canine Arthritis Management, Hannah Capon and veterinary communications consultant, Zoe Belshaw to produce a number of online and in-practice tools.
The first of these is a worksheet to help veterinary surgeons explain the impact of OE on the client's dog, both in and outside the home. It provides a template for creating a tailored management plan and a guide to the home adaptations owners can make to help improve their dog's quality of life.
The company has also produced a infographic fact sheet which explains the subtle signs of OA, designed for vets and nurses to use as part of their regular interactions with owners.
Elanco has also designed a range of digital materials for veterinary practices to use on their websites and social media feeds to increase awareness of the condition among their online communities.
Hannah Capon said: "Arthritis affects every dog differently – a dog may be full of life but lame, quiet, unenthused and slow to move, or somewhere in-between.
"Home management needs to be tailored to each dog’s needs and adapted in the same way it would be for a person, to prolong life and minimise pain and further injury."
Lastly, Elanco has also produced a film in which Zoe Belshaw gives advice about the language and strategies veterinary surgeons can use to help improve communication with dog owners about OA.
Zoe said: "My research identified that many owners do recognise their arthritic dog has a problem before it’s diagnosed. Many will have seen that their dog is stiff, or ‘slowing down’ but they may not associate this with lameness, or pain.
"That’s why vets, nurses and practices play a critical role in raising awareness of how the condition impacts dogs every day."
To access the suite of assets visit: www.myelanco.co.uk
Dr Fures was convicted of driving with excess alcohol in the Dublin Criminal Courts of Justice in December 2018.
Later, when renewing his UK RCVS registration, Dr Fures told the RCVS Chief Investigator that on the day of his offence, he'd been on a flight from Frankfurt to Dublin which suffered engine failure, causing the pilot to perform a forced emergency landing in Amsterdam. There, he claimed, the passengers switched to an airworthy plane for the rest of the journey, during which he had several drinks to calm his nerves.
In a remarkably detailed and complex investigation, the RCVS Chief Investigator rang Lufthansa and discovered that the flight had not suffered engine failure and had flown direct from Frankfurt to Dublin without incident.
In May and July 2020, the RCVS Chief Investigator wrote to Dr Fures setting out the result of his investigations and research. In his responses Dr Fures accepted that his memory of the incident was wrong.
At the outset of the hearing Dr Fures made an application to the Committee enter into undertakings to voluntarily remove himself from the UK Register and to not apply to re-join. However, the Committee did not accept these undertakings in part on the basis that he was not of retirement age and intended to continue to practise in Ireland.
The Committee considered that if it were to accept his undertakings, then there would be no judgement or findings that could be passed on to the Veterinary Council of Ireland for consideration via its own disciplinary procedures.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee decided that this is a case in which the public interest, confidence in the profession, and, potentially, the welfare of animals, demands that there be a full hearing, with determinations made by the Disciplinary Committee."
The Committee then went on to consider the facts of the case.
Dr Fures admitted that he had supplied the RCVS with false information about his conviction for drink driving but denied that this was dishonest at the time that he supplied the information. He accepted that the information he provided was wrong, in that his flight between Frankfurt and Dublin, while delayed by just over an hour, did not have to land in Amsterdam as he had previously claimed.
He said that his false statement was based on misremembering the circumstances and that he had genuinely believed his statement was true at the time it was made to the RCVS. He said that, due to shame over his conviction and the negative impact it had on the life of him and his family, he had created a false memory of the circumstances.
However, the Committee was not persuaded that there was any other explanation in this case, other than that Dr Fures deliberately and dishonestly gave false information to the RCVS, to excuse his behaviour.
The Committee then considered if the admitted and proven charges amounted to serious professional misconduct.
Ian said: “The Committee was of the view that Dr Fures’ actions in dishonestly giving false details to his regulator was serious. While it was the case that there was no actual harm or risk to animals arising out of his conduct, the Committee took into account that the dishonest account was given deliberately.
“In addition, it was sustained, in that it was relied upon and expanded upon on several occasions when the College sought further clarity. Dr Fures had the opportunity to correct the situation, and give the truthful account, but he did not do so. The dishonesty was designed to achieve personal gain to Dr Fures, in that he wished to minimise the actions which the College may take against him, and, in consequence, safeguard his career.
“Dr Fures’ action in dishonestly giving false information to his regulator struck at the heart of his obligation, as a registered professional, to be open and honest with his regulator. This obligation is necessary to allow the College, as regulator, to carry out its crucial and statutory functions in ensuring that it investigates concerns properly.”
In considering the sanction for Dr Fures, the Committee took into account the mitigating factors, including the fact that there were no previous regulatory findings against Dr Fures or any previous conviction for dishonesty, that he had demonstrated remorse for his actions, that there was no actual harm or risk of harm to any animal, that no concerns raised about Dr Fures’ practice, that there was no repetition of the dishonest conduct and that he had demonstrated some insight.
However, in terms of aggravating factors it considered that there was deliberate and sustained dishonesty and that he had sought personal gain as a result of his actions.
After considering various options, the Committee decided that a reprimand and warning as to future conduct was the most appropriate sanction for Dr Fures.
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Ms Mulvey faced a total of nine charges against her:
Ms Mulvey did not respond to the charges, was not present at the hearing and was not represented.
She told the College that she couldn't attend for health reasons, but did not then provide any medical evidence and did not apply for a remote hearing, which was offered.
She had appeared before the Disciplinary Committee twice previously, facing a number of similar charges.
In 2016/2017, Ms Mulvey admitted all charges she was faced with and was found guilty of disgraceful conduct in a professional respect.
The Committee then decided to postpone the sanction for a period of one year.
In 2019, Ms Mulvey appeared before the Committee for the resumed sanction hearing and faced further new charges relating to failures to provide clinical history, failing to communicate with clients, failing to respond to requests for information from the College concerning complaints made against her, continuing professional development and indemnity insurance.
Ms Mulvey admitted the new charges and that she was guilty of disgraceful conduct in a professional respect, for which she was struck off for six months.
Taking into account the fact that this was not Ms Mulvey’s first time before the Committee, as well as new accompanying evidence, the Committee considered the facts of each subsection of each charge individually.
The Committee found all charges proved, apart from one subsection of charge 1.
The Committee then went on to decide if Ms Mulvey was guilty of disgraceful conduct in a professional respect, noting that it was entitled to consider the facts on a cumulative basis.
In other words, whilst any one charge may not fall far below the relevant standard expected of a veterinary surgeon on a standalone basis, it may when considered in conjunction with other failings that have been found proved.
The Committee found a number of aggravating factors in the case, including actual injury to animals (including death and amputation), dishonesty, breach of trust, sustained behaviour, disregard of the role of the RCVS, lack of insight by the defendant and previous adverse findings.
There were no mitigating factors.
The Committee then went on to decide upon a sanction.
Paul Morris, chairing the Committee and speaking on its behalf, said: “The Committee found that Dr Mulvey has demonstrated a wilful disregard for the role of her regulator and the systems that regulate the profession which are designed to ensure animal welfare.
"She has failed to learn from, or respond to in any meaningful way, her previous appearances before her regulator and advice given.
"The instant charges found proved dated back to shortly after the earlier suspension had elapsed.
"The Committee further noted that, if a period of suspension were to be imposed, at the end of the suspension Dr Mulvey would be entitled to resume practice without any preconditions.
“This is a case involving serious malpractice.
"It was sustained over a period of time.
"It followed previous adverse findings for almost identical failures.
"From as long ago as 2013, Dr Mulvey was given ample opportunity and support to remedy the deficiencies in her practice, which she squandered.
"Dr Mulvey’s conduct had very serious consequences for animal welfare.
"She continued, and continues, to display a wilful disregard for her responsibilities as a veterinary surgeon under the Code of Professional Conduct.
"Dr Mulvey’s conduct was a gross departure from the conduct expected of a veterinary surgeon.
“Dr Mulvey’s disgraceful conduct is so serious that removal from the Register is the only means of protecting animals and the wider public interest which includes protection of the public, the maintenance of public confidence in the profession, and the upholding of standards.”
Dr Mulvey has 28 days from being notified of her removal from the Register to lodge an appeal with the Privy Council.
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
In addition to working as a clinician in private practice and for charity, Gudrun has worked in several veterinary-related roles in industry, both in management and as a consultant, as well as being the Chair for the British Veterinary Association’s Good Veterinary Workplace Working Group.
In the new role, Gudrun will work support the implementation of the British Veterinary Association’s Good Veterinary Workplaces Code across the business.
Gudrun said: “Having been heavily involved in the work leading up to the Good Veterinary Workplaces Code during my time at the British Veterinary Association, I can fully relate to the many pressures that veterinary workplaces are currently under.
"Through supportive action and using evidence-based tools, I believe we can make a positive and lasting difference.
“It’s an honour to join Vets4Pets as we begin to implement its many commitments to improving the industry.
"I am excited to work towards a positive future for veterinary workplaces and being able to work with Vets4Pets to build a well-resourced and accessible tool for practices to implement good veterinary workplaces will help our practices to attract and retain the best clinical talent.”
AB Science, a young Paris-based biotech company, has announced the pan-European commercial launch of its veterinary anticancer drug, Masivet
Masivet was approved in November 2008 by the European Medicines Agency (EMEA) for the treatment of dogs with non-resectable grade 2 or 3 mast cell tumours. Masivet's active pharmaceutical ingredient is masitinib, a tyrosine kinase inhibitor. Masitinib, discovered and developed by AB Science, belongs to a therapeutic class of drug known as targeted therapy that is, according to AB Science, revolutionising the treatment of cancer in humans.
Alain Moussy, CEO of AB Science said: "Masivet is the first product ever registered as a cancer treatment in veterinary medicine. AB Science is a dynamic and very entrepreneurial biotech company, and is proud to have introduced a drug that can extend the life of dogs suffering from cancer ahead of the large pharmaceutical companies".
The company says Mastocytoma can be an aggressive cancer with a poor prognosis, and represents up to 20% of all cutaneous canine tumours. Some breeds are particularly susceptible, among them Golden Retrievers, Labradors and Boxers. Cancers have the same prevalence in dogs as in humans (1 dog in 4 will suffer from cancer during its lifetime) but surprisingly, no drugs developed for veterinary medicine with a demonstrated efficacy and safety have ever been approved until the arrival of Masivet.
The company claims two main benefits of the new treatment:
AB Science is a biotech company specialising in developing targeted drugs for high need indications, such as cancers, chronic inflammatory diseases and neurodegenerative disorders. Masitinib is the most advanced drug in the pipeline. Now being marketed in veterinary medicine, masitinib is also under development in humans, with phase 3 clinical studies in pancreatic cancer and in gastrointestinal stromal tumour (GIST).
Alain Moussy said: "This registration in veterinary medicine is good news for the future success of masitinib in humans, for whom we are aggressively developing it in cancers and other indications with high morbidity or pain.
"It is very unusual to develop such an innovative product simultaneously in veterinary and human medicines, and even more so that the product is registered in veterinary medicine first. There is no doubt that experts in human oncology will be watching Masivet's future very closely from now on.. However, people will have to wait a while before benefiting from masitinib because it is unlikely to be available to man before 2012".
For more information, see www.masivet.com and www.ab-science.com
Royal Canin has launched two new skincare diets.
'Hypoallergenic Wet' is a wet adaptation of its 'Hypoallergenic' range of diets, providing variety for the nutritional management of dogs with adverse food reactions. 'Anallergenic' dry food is for the dietary management of dogs with even the most severe dietary allergy.
'Hypoallergenic Wet' contains soy protein hydrolysate, so it can either be fed as a complete diet or interchanged and used as an addition to Hypoallergenic, Hypoallergenic Moderate Calorie or Hypoallergenic Small Dog. The wet food, available in a 400g can, can be recommended for short term feeding (for an elimination diet strategy) or for the lifelong nutritional management of dogs with adverse food reactions. Royal Canin says it is designed to be highly digestible through its low molecular weight peptides and is also appropriate for the dietary support of dogs with inflammatory bowel disease, chronic diarrhoea and Exocrine Pancreatic Insufficiency (EPI).
'Anallergenic' follows in the footsteps of Hypoallergenic but goes further - offering both hydrolysed proteins and a pure carbohydrate source, to which exposure is limited and therefore allergy would be rare. The diet comprises a unique protein source composed exclusively of free amino acids and very low molecular weight oligopeptides. Much like the Hypoallergenic range, Anallergenic is also formulated with essential fatty acids to help support skin health and a complex of nutrients to help maintain the barrier effect of the skin.
The fully balanced diet - suitable for the nutritional support of adult dogs either short or long-term - has proven results with 100% of dogs in a Royal Canin study showing significant improvement in their skin condition.
Gudi Stuttard BVSc MRCVS, one of Royal Canin's Veterinary Support Managers, said: "These two new products join our well-established 'Hypoallergenic' range, as well as our recently launched 'Skin Care' diets - for the nutritional management of dogs with dermatosis unrelated to food intolerance or allergy.
"By building on our portfolio of veterinary skin care diets, we aim to further strengthen our DermAlliance campaign, which is dedicated to assisting in the improvement of skin care knowledge in general veterinary practice."
Please visit www.royalcanin.co.uk for more information.
According to the company, the new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM). Twelve hours after the injection is administered, treatment can be continued by the dog's owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
Ruth Willis BVM&S DVC MRCVS, RCVS Recognised Specialist in Cardiology said: "Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM."
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25 kg.
In association with the Vets Now emergency treatment service, Boehringer has produced an algorithm which features step-by-step guidance on the recommended treatment protocol for dogs with acute congestive heart failure due to MVD or DCM, together with point of sale material including shelf wobblers for use in practice to raise awareness of the product.
The company is also hosting a free cardiology webinar presented by Ruth Willis entitled 'Acute CHF - a stress free approach'. The online seminar takes place at 8.00pm on Tuesday 19 February and counts for one hour's CPD. The webinar will be available to view after the live event on demand. To register, visit http://www.bi-academy.co.uk/.
For further information, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
Ludivine, who graduated in 2008, has come over from America to take up the new post, having just completed a three-year residency at the University of Pennsylvania in Philadelphia.
She said: "I’m really enjoying working as part of a great team and working with the various different disciplines here.
"I’m passionate about my ECC speciality and I have a keen interest in respiratory diseases, trauma and acid base disturbances.
"I also like teaching and being updated about the most recent studies in ECC to ensure I can deliver the most up-to-date care possible for our patients."
Ludivine was born in France and originally studied at her home town university in Lyon, progressing to a rotating internship there after graduation.
In 2012, she worked as an emergency veterinary surgeon in several general practices across France and Switzerland, before moving to the United States in 2014 to see how ECC medicine was practiced overseas.
First, she undertook an ECC internship at the University of California, followed by a three-year residency at the University of Pennsylvania.
Away from work, Ludivine enjoys horse riding, running, work-outs and practising her skiing in the French Alps. She also has two dogs Dalhi her Golden Retriever and Baya her German Shepherd.
For more information, visit www.willows.uk.net/en-GB/specialist-services.
The RCVS has released the photograph of a man apprehended by Wiltshire police whilst working as a bogus veterinary surgeon at a practice in Swindon.
Peter Keniry, who had been practising under the name of a properly qualified and legitimately registered veterinary surgeon Shaun Kehoe, was arrested on 23 August and appeared in Swindon Magistrates' Court on charges of fraud and practising veterinary surgery unlawfully. He was released on bail.
Mr Keniry is no stranger to the College or the police, and has already been dealt with in 1998, 2001 and 2005 for similar offences. On each occasion, Mr Keniry has impersonated a member of the College whose name is legitimately on the Register, which makes it difficult even for practices that do check the credentials of prospective employees.
Gordon Hockey, Head of Professional Conduct and Assistant Registrar at the RCVS said: "We were alerted to the potential fraud on 23 August and immediately liaised with the police to facilitate Mr Keniry's arrest that same day. The next day, RCVS Council member Dr Bob Moore and I visited Swindon police station to assist the police.
"It appears that Mr Keniry has continued his pattern of re-offending, and we hope that by publicising his photograph any other practice that has employed him recently will recognise him and contact the RCVS Professional Conduct Department, and potential employers and locum agencies will keep his photograph to reduce the chances of this happening again."
The RCVS Professional Conduct Department can be contacted on: profcon@rcvs.org.uk or 020 7202 0789.
Veterinary medicines are defined in the Veterinary Medicines Regulations as:
"any substance or combination of substances that may be used in, or administered to, animals with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis."
On this basis, the VMD says CBD products for use in animals require a marketing authorisation before they can be sold or supplied in the UK.
There are currently no CBD based products that have been granted a UK veterinary marketing authorisation which means that under the cascade, veterinary surgeons must prescribe a legally obtained human CBD product.
Photo: Shutterstock / Lifestyle discover
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Evidence given to the Women and Equalities parliamentary committee by BUPA last year suggested that 900,000 women may have left the UK workforce in recent years as a result of menopausal symptoms.
With the veterinary profession increasingly female in composition it is hoped that the hub will support more women to stay in the profession and therefore retain their vital skills in the workforce.
Statistics from the Voice of the Veterinary Profession Spring 2023 survey showed that only 14% of vets are aware of a menopause policy at their workplace, while 46% say there is no policy and 39% are unsure.
The survey also revealed that only 59% of vets would feel confident supporting a colleague experiencing menopause.
The new menopause hub provides veterinary specific menopause content to support everyone working in practice including colleagues, managers and partners of people experiencing menopause.
BVA recently signed the Menopause Workplace Pledge – committing to take positive action to make sure everyone experiencing menopause is supported - and is now urging other veterinary employers to do the same.
British Veterinary Association Junior Vice President Anna Judson, said: “We know that menopause is of growing importance to our profession, with female vets now making up more than half the workforce, and we know that issues with managing menopause symptoms prompt a significant number of women to move away from clinical work.
“As part of our Good Veterinary Workplaces campaign we’re committed to supporting all veterinary staff affected by menopause, allowing them to remain in post, and to providing relevant resources to improve employer engagement in this area.
"We urge all veterinary workplaces to sign the pledge and consider what more they could be doing to support their staff in managing menopause symptoms in the workplace.”
BVA members experiencing menopause are also eligible for 3 months free access to the Stella app, which includes a personalised plan to manage your specific symptoms, real-life coach support, menopause resources, progress tracking, and a supportive community.
Content on the Stella app is created in collaboration with a range of clinicians and healthcare professionals and goes through a rigorous fact-checking and review process.
https://www.bva.co.uk/menopause-hub
The RCVS Disciplinary Committee has this week directed that the name of a Grimsby veterinary surgeon should be removed from the RCVS Register, having found him guilty of serious professional misconduct for advising and undertaking surgical procedures without sufficient clinical grounds or considering alternative treatment options; failing to obtain the informed consent of his clients; undertaking procedures outside his area of competence; failing to refer or discuss the option of referral to a specialist; and, failing to provide his patients with adequate pain relief.
Mr Joseph Lennox Holmes, of Waltham Veterinary Clinic, Grimsby, faced nine charges relating to two separate complaints, at a two-week hearing in October which resumed this week.
These complaints concerned four consecutive staphylectomies and a tracheostomy that Mr Holmes performed on Jake, a Cavalier King Charles Spaniel owned by Ms Marsden; the dental treatment he gave to three Persian cats called Dream Topping, Charlie Brown and Henry, together with the advice he gave to their owner, Mrs Auckland.
On 25 October 2007, Mr Holmes performed a staphylectomy on Jake during dental surgery. He gave the Committee various reasons why he thought the procedure was necessary; however, the Committee accepted the opinion of two expert witnesses Professor Dan Brockman, a specialist in soft tissue surgery at the Royal Veterinary College, and Mr Andrew Ash, the senior veterinary surgeon at a 17-vet small animal practice, that there were insufficient clinical grounds for such a surgical procedure to be undertaken. The Committee also found Mr Holmes had not adequately considered other treatments, or obtained fully informed consent from Jake's owner for this procedure.
Mr Holmes performed further staphylectomies and a tracheostomy on Jake, a procedure described by Professor Brockman as "by definition, high risk and best performed by a specialist". He did not consider referral, or inform Mrs Marsden that such referral was an option. Nor did he provide sufficient aftercare or pain relief. Following these surgeries, Jake was euthanased .
In the second complaint, Mr Holmes performed dental extractions on two cats, Dream Topping and Henry, and advised removing teeth from a third, Charlie Brown, in October 2008. The Committee, however, accepted the view of expert witness Mr Ash and Dr David Crossley, RCVS Recognised Specialist in Veterinary Dentistry, that the dental extractions performed, and the advice given, were not justified on the available clinical evidence. The Committee also found that Mr Holmes did not discuss alternative treatment options with Mrs Auckland, or obtain her informed consent. In the case of Dream Topping, consent was sought after the cat had been sedated for an unrelated procedure and Mrs Auckland had felt under pressure to consent.
Mr Holmes had also relied on anaesthesia-inducing drugs to provide analgesia for the dental extractions, without any other form of pain relief. The Committee agreed with the expert witnesses that this was wholly inadequate.
The Committee found many aggravating factors in both cases, including actual injury to animals from unnecessary surgery, and a serious breach of the trust in which Mr Holmes' clients had placed in him to make the welfare of their animals his primary consideration. His repeated misconduct had been sustained over a period of time in the face of a previous adverse finding of the Committee in 2006.
It also found that Mr Holmes failed to appreciate when a case was outwith his experience, and had continued his course of action despite Jake's deterioration; he had not considered referral or accepted that others in the profession might know more than he did; in formulating clinical practice and policies, he made no reference to peer-reviewed literature or continued professional development; and, his use of outmoded drugs and medicines intended for human use was of concern, as was his lack of appreciation of the need for adequate pain relief when performing painful surgical procedures.
Towards the end of the hearing, Mr Holmes said in mitigation that he regretted unreservedly any adverse effects that his treatment had had on the animals concerned, and that he now realised that his long history of working alone had allowed him to become professionally isolated, to become over-confident in the value of his own experience and rather "set in his ways".
Having given serious consideration to postponing judgment, subject to undertakings from Mr Holmes, Disciplinary Committee Chairman Mrs Caroline Freedman said: "We are mindful that the sanction which we apply must be proportionate to the nature and extent of the misconduct found proved and must balance the public interests against the interests of the Respondent.
"We are, however, also mindful of Mr Holmes' conduct during the previous 11½ days of the hearing, during which time his every action was vigorously defended and no insight whatsoever was shown."
The Committee also considered suspending Mr Holmes from the Register. "In view of the serious and long-term nature of the conduct found proved in the charges, we do not feel that it is appropriate that Mr Holmes should be permitted to return to the Register without further assessment of his efforts to update his knowledge," said Mrs Freedman, before concluding: "The only appropriate sanction in each case is that the Registrar be directed to remove Mr Holmes' name from the Register."